Toon Van Gorp

European Union
Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 163 publications

Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study.

Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study.

Journal: Gynecologic oncology
Published: May 23, 2026

Reconsidering the control arm in hyperthermic intra-peritoneal chemotherapy trials for epithelial ovarian cancer: are we comparing equivalent chemotherapy exposure?

Reconsidering the control arm in hyperthermic intra-peritoneal chemotherapy trials for epithelial ovarian cancer: are we comparing equivalent chemotherapy exposure?

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 12, 2026

Patients' Perception of Follow-Up Care and Personal Health Status of 677 Long-Term Survivors of Gynecological Cancer from the Study "Expression IX-Long-Term Survival with Gynecological Cancer": The International NOGGO, ENGOT and GCIG Survey.

Patients' Perception of Follow-Up Care and Personal Health Status of 677 Long-Term Survivors of Gynecological Cancer from the Study "Expression IX-Long-Term Survival with Gynecological Cancer": The International NOGGO, ENGOT and GCIG Survey.

Journal: Cancers
Published: February 18, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)
Published: February 10, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology
Published: February 02, 2026

Pre-operative assessment in International Federation of Gynaecology and Obstetrics-2009 stage IB2 to IIB cervical cancer: role of delayed gadolinium-enhanced magnetic resonance imaging after neoadjuvant chemotherapy.

Pre-operative assessment in International Federation of Gynaecology and Obstetrics-2009 stage IB2 to IIB cervical cancer: role of delayed gadolinium-enhanced magnetic resonance imaging after neoadjuvant chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 16, 2025

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Future oncology (London, England)
Published: December 12, 2025

Impact of atypical extra-villous trophoblast foci on the natural history and management of post-molar gestational trophoblastic neoplasia.

Impact of atypical extra-villous trophoblast foci on the natural history and management of post-molar gestational trophoblastic neoplasia.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 09, 2025

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

Journal: British journal of cancer
Published: November 24, 2025

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Research square
Published: November 19, 2025

A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: October 14, 2025

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
Showing 1-12 of 163

Last Updated: 09/26/2026